Statin use and breast cancer survival - a Swedish nationwide study.
Breast cancer
Prognosis
Statin
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
11 Jan 2019
11 Jan 2019
Historique:
received:
14
06
2018
accepted:
28
12
2018
entrez:
13
1
2019
pubmed:
13
1
2019
medline:
24
4
2019
Statut:
epublish
Résumé
A sizeable body of evidence suggests that statins can cease breast cancer progression and prevent breast cancer recurrence. The latest studies have, however, not been supportive of such clinically beneficial effects. These discrepancies may be explained by insufficient power. This considerably sized study investigates the association between both pre- and post-diagnostic statin use and breast cancer outcome. A Swedish nation-wide retrospective cohort study of 20,559 Swedish women diagnosed with breast cancer (July 1st, 2005 through 2008). Dispensed statin medication was identified through the Swedish Prescription Registry. Breast cancer related death information was obtained from the national cause-of-death registry until December 31st, 2012. Cox regression models yielded hazard ratios (HR) and 95% confidence intervals (CI) regarding associations between statin use and breast cancer-specific and overall mortality. During a median follow-up time of 61.6 months, a total of 4678 patients died, of which 2669 were considered breast cancer related deaths. Compared to non- or irregular use, regular pre-diagnostic statin use was associated with lower risk of breast cancer related deaths (HR = 0.77; 95% CI 0.63-0.95, P = 0.014). Similarly, post-diagnostic statin use compared to non-use was associated with lower risk of breast cancer related deaths (HR = 0.83; 95% CI 0.75-0.93, P = 0.001). This study supports the notion that statin use is protective regarding breast cancer related mortality in agreement with previous Scandinavian studies, although less so with studies in other populations. These disparities should be further investigated to pave the way for future randomized clinical trials investigating the role of statins in breast cancer.
Sections du résumé
BACKGROUND
BACKGROUND
A sizeable body of evidence suggests that statins can cease breast cancer progression and prevent breast cancer recurrence. The latest studies have, however, not been supportive of such clinically beneficial effects. These discrepancies may be explained by insufficient power. This considerably sized study investigates the association between both pre- and post-diagnostic statin use and breast cancer outcome.
METHODS
METHODS
A Swedish nation-wide retrospective cohort study of 20,559 Swedish women diagnosed with breast cancer (July 1st, 2005 through 2008). Dispensed statin medication was identified through the Swedish Prescription Registry. Breast cancer related death information was obtained from the national cause-of-death registry until December 31st, 2012. Cox regression models yielded hazard ratios (HR) and 95% confidence intervals (CI) regarding associations between statin use and breast cancer-specific and overall mortality.
RESULTS
RESULTS
During a median follow-up time of 61.6 months, a total of 4678 patients died, of which 2669 were considered breast cancer related deaths. Compared to non- or irregular use, regular pre-diagnostic statin use was associated with lower risk of breast cancer related deaths (HR = 0.77; 95% CI 0.63-0.95, P = 0.014). Similarly, post-diagnostic statin use compared to non-use was associated with lower risk of breast cancer related deaths (HR = 0.83; 95% CI 0.75-0.93, P = 0.001).
CONCLUSION
CONCLUSIONS
This study supports the notion that statin use is protective regarding breast cancer related mortality in agreement with previous Scandinavian studies, although less so with studies in other populations. These disparities should be further investigated to pave the way for future randomized clinical trials investigating the role of statins in breast cancer.
Identifiants
pubmed: 30634941
doi: 10.1186/s12885-018-5263-z
pii: 10.1186/s12885-018-5263-z
pmc: PMC6330431
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Références
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):250-8
pubmed: 17245804
Breast Cancer Res Treat. 2008 Jun;109(3):573-9
pubmed: 17674197
Endocrinol Metab Clin North Am. 2008 Sep;37(3):663-84, ix
pubmed: 18775358
J Clin Oncol. 2011 Jan 1;29(1):25-31
pubmed: 21115856
J Natl Cancer Inst. 2011 Oct 5;103(19):1461-8
pubmed: 21813413
Cancer Invest. 2011 Nov;29(9):585-93
pubmed: 21936625
Oncogene. 2012 Nov 29;31(48):4967-78
pubmed: 22310279
N Engl J Med. 2012 Nov 8;367(19):1792-802
pubmed: 23134381
Stat Med. 2014 Feb 28;33(5):881-99
pubmed: 24027094
PLoS One. 2013 Sep 25;8(9):e75088
pubmed: 24086446
Science. 2013 Nov 29;342(6162):1094-8
pubmed: 24288332
Breast Cancer Res Treat. 2014 Apr;144(2):405-16
pubmed: 24557337
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
Cancer Res. 2014 Sep 15;74(18):4976-82
pubmed: 25060521
Lancet Oncol. 2014 Sep;15(10):e461-8
pubmed: 25186049
Epidemiology. 2015 Jan;26(1):68-78
pubmed: 25304447
PLoS One. 2014 Oct 20;9(10):e110231
pubmed: 25329299
Cell. 2015 Mar 26;161(1):161-172
pubmed: 25815993
Clin Cancer Res. 2015 Aug 1;21(15):3402-11
pubmed: 25840970
Cancer Treat Rev. 2015 Jun;41(6):554-67
pubmed: 25890842
J Transl Med. 2015 Apr 29;13:133
pubmed: 25925673
Oncotarget. 2015 Dec 15;6(40):42988-3004
pubmed: 26472026
Int J Cancer. 2016 Sep 15;139(6):1281-8
pubmed: 27176735
J Med Screen. 2017 Mar;24(1):34-42
pubmed: 27306511
Oncotarget. 2016 Sep 13;7(37):59640-59651
pubmed: 27458152
Br J Cancer. 2016 Aug 23;115(5):592-8
pubmed: 27482648
BMC Cancer. 2016 Aug 04;16:600
pubmed: 27491389
Nat Cell Biol. 2016 Nov;18(11):1233-1243
pubmed: 27775703